Revisiting Immunotherapy: A Focus on Prostate Cancer.
Revisiting Immunotherapy: A Focus on Prostate Cancer.
复制标题
DOI：
10.1158/0008-5472.can-19-2948
复制
发表时间：
2020-04-15
期刊：
影响因子：
11.2
通讯作者：
Ponnazhagan S
中科院分区：
文献类型：
--
作者：
Cha HR;Lee JH;Ponnazhagan S
利用免疫系统对抗肿瘤细胞的治疗性干预在过去为几种实体瘤和血液恶性肿瘤提供了混合的结果。然而，免疫疗法在过去十年中取得了相当大的进展，并正在成为治疗晚期实体瘤患者的一种不可或缺的组合。特别是，前列腺癌（PCa）免疫疗法在过去对患者显示出适度的疗效。随着最近在免疫机制和先进分子诊断平台上的几项关键发现，免疫治疗重新成为PCa，特别是去势抵抗性前列腺癌（CRPC）刺激抗肿瘤免疫的可行选择。将患者定制的免疫治疗和免疫检查点阻断剂与传统的细胞毒性药物和雄激素受体（AR）靶向治疗相结合，应该会推动该领域的发展。随着最近的适应，免疫检查点抑制剂的应用已经成功地治疗了十几种实体瘤，包括黑色素瘤，淋巴瘤，肝癌，宫颈癌，胃肠道和乳腺癌，这是一个及时的奋进，利用免疫治疗PCa。在这里，我们提供了一个关于免疫治疗进展的帐户，新的发现和精确的方法用于肿瘤，特别是CRPC，从机制的角度来看，新兴的限制和未来的方向。
Therapeutic interventions to harness the immune system against tumor cells have provided mixed results in the past for several solid tumors and hematologic malignancies. However, immunotherapy has advanced considerably over the last decade and is becoming an integral combination for treating patients with advanced solid tumors. In particular, prostate cancer (PCa) immunotherapy has shown modest efficacy for patients in the past. With several key discoveries on immune mechanisms and advanced molecular diagnostic platforms recently, immunotherapy is re-emerging as a viable option for PCa, especially castration-resistant prostate cancer (CRPC), to stimulate anti-tumor immunity. Combination of patient-tailored immunotherapy and immune checkpoint blockers with conventional cytotoxic agents and androgen receptor (AR)-targeted therapies should move the field forward. With a recent adaptation that the application of immune checkpoint inhibitors has been successful in the treatment of more than a dozen solid tumors, including melanoma, lymphoma, liver, cervical, gastrointestinal, and breast cancers, it is a timely endeavor to harness immunotherapy for PCa. Here, we provide an account on the progression of immunotherapy with new discoveries and precision approaches for tumors, in particular CRPC, from mechanistic standpoint to emerging limitations and future directions.